The Community Focus Channel on VJHemOnc is an independent medical education platform, supported with funding from Johnson & Johnson (Gold). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Myeloproliferative Neoplasms Channel on VJHemOnc is an independent medical education platform, supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
MPN Workshop of the Carolinas 2024 | Personalizing the timing of SCT in patients with myelofibrosis
Stem cell transplantation (SCT) remains the only curative therapeutic approach for patients with myelofibrosis (MF); however, it is associated with a transplant-related mortality of between 10-20%. Rami Komrokji, MD, Moffitt Cancer Center, Tampa, FL, discusses the complex matter of deciding whether a patient with MF should undergo SCT and how the timing of transplantation may need to be personalized to the individual. In patients where it is unclear if the disease is at high risk of progression, the trajectory of the disease may be studied for some time before a decision regarding transplantation is made. This interview took place at the 1st Annual MPN Workshop of the Carolinas in Asheville, NC.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
